EPISODE · Jun 30, 2021 · 39 MIN
HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
from touchPODCAST · host touchpodcast
touchEXPERT OPINIONS for touchONCOLOGY Listen to leading experts in breast cancer share their opinion on the latest data which may help guide the use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer. The experts Dr Luca Malorni - Hospital of Prato, Italy Prof. Aleix Prat - Hospital Clínic Barcelona, Spain Dr Barbara Pistilli - Gustave Roussy, Villejuif, France This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Novartis and is provided by touchIME. For further information visit our website: https://touchoncology.com/education/cdk-inhibitors-breast-cancer/
Embed this episode
Ready to play
HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.